US4316904A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Indolopyrone tetrazoles and carboxamidotetrazoles having antiallergic activity
Assignee: Warner Lambert Co LLC
•
Filing: 1979-09-25
•
Granted: 1982-02-23
•
Expires: 1999-09-25
Abstract
Abstract Certain novel indolopyrone tetrazoles, carboxamidotetrazoles and their pharmaceutically acceptable salts are disclosed. These compounds are useful as antiallergic agents in mammals.
Inventors
- 👤 Richard E. Brown
- 👤 Paul C. Unangst
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 06:59
CPC Classifications
C; C07; C07D; C07D491/00; C07D491/02; C07D491/04
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
27 words
A compound having the structural formula ##STR8## wherein R 1 is alkyl of from 1 to 6 carbon atoms or phenyl, and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
27 words
A compound having the structural formula ##STR8## wherein R 1 is alkyl of from 1 to 6 carbon atoms or phenyl, and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
22 words
The compound as defined in claim 1 wherein R is hydrogen, R 1 is methyl, ##STR9## and the pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
25 words
The compound as defined in claim 1 wherein R is hydrogen, R 1 is ethyl, R 2 is ##STR10## and the pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim
22 words
The compound as defined in claim 1 wherein R is hydrogen, R 1 is phenyl, ##STR11## and the pharmaceutically acceptable salts thereof.
Claim 6
Dependent Claim
13 words
A compound having the structural formula ##STR12## and the pharmaceutically acceptable salts thereof.
Claim 7
Dependent Claim
13 words
A compound having the structural formula ##STR12## and the pharmaceutically acceptable salts thereof.
Claim 8
Dependent Claim
13 words
A compound having the structural formula ##STR13## and the pharmaceutically acceptable salts thereof.
Claim 9
Dependent Claim
13 words
A compound having the structural formula ##STR13## and the pharmaceutically acceptable salts thereof.
Claim 10
Dependent Claim
22 words
The compound as defined in claim 6 wherein R is 8-chloro, R 1 is methyl, ##STR14## and the pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim
22 words
The compound as defined in claim 6 wherein R is 8-chloro, R 1 is methyl, ##STR15## and the pharmaceutically acceptable salts thereof.
Claim 12
Dependent Claim
13 words
A compound having the structural formula ##STR16## and the pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
13 words
A compound having the structural formula ##STR16## and the pharmaceutically acceptable salts thereof.
Claim 14
Dependent Claim
22 words
The compound as defined in claim 9 wherein R is 8-methyl, R 1 is methyl, ##STR17## and the pharmaceutically acceptable salts thereof.
Claim 15
Dependent Claim
22 words
The compound as defined in claim 9 wherein R is 8-methyl, R 1 is methyl, ##STR18## and the pharmaceutically acceptable salts thereof.
Claim 16
Dependent Claim
19 words
A compound having the structural formula ##STR19## wherein R is hydrogen or nitro, and the pharmaceutically acceptable salts thereof.
Claim 17
Dependent Claim
19 words
A compound having the structural formula ##STR19## wherein R is hydrogen or nitro, and the pharmaceutically acceptable salts thereof.
Claim 18
Dependent Claim
25 words
The compound as defined in claim 12 wherein R is 8-nitro, R 1 is methyl, R 2 is ##STR20## and the pharmaceutically acceptable salts thereof.
Claim 19
Dependent Claim
23 words
The compound of claim 12 wherein R is 6,8-dinitro, R 1 is methyl, R 2 is ##STR21## and the pharmaceutically acceptable salts thereof.
Claim 20
Dependent Claim
35 words
A pharmaceutical composition for preventing the allergic response in a mammal comprising an antiallergic effective amount of a compound as defined in claims 1, 5, 6, 9 or 12, and the pharmaceutically acceptable salts thereof.
Claim 21
Dependent Claim
28 words
A method of preventing the allergic response in a mammal which comprises administering to said mammal an antiallergic effective amount of a composition as defined in claim 15.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-02-22 | 1985-08-24 | 1986-02-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-02-22 | 1989-08-24 | 1990-02-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-02-22 | 1993-08-24 | 1994-02-23 | $7700.00 | Window Closed / Lapsed |